KYTX

U.S. Stock Market Performance: U.S. stocks declined slightly, with the Dow Jones falling about 0.1% on Thursday, while several companies reported strong earnings and raised their guidance.

Donaldson Company Earnings: Donaldson Company, Inc. saw a 4.7% increase in its stock price after reporting a 3.9% year-over-year sales growth and raising its fiscal 2026 adjusted EPS guidance.

Notable Stock Gains: UiPath Inc. and Science Applications International Corporation experienced significant stock price increases of 16.5% and 15.8%, respectively, following better-than-expected financial results and raised guidance.

Other Companies with Gains: Several other companies, including ASP Isotopes Inc. and BioAge Labs, also saw notable stock price increases due to positive financial news and analyst ratings.

U.S. Stock Futures: U.S. stock futures rose this morning, with Nasdaq futures increasing by approximately 300 points on Thursday.

Palo Alto Networks Performance: Palo Alto Networks reported strong first-quarter results for fiscal 2026, with revenue of $2.47 billion and adjusted earnings of 93 cents per share, both exceeding analyst expectations, despite a 4.6% drop in pre-market trading.

Other Stocks Declining: Several stocks experienced declines in pre-market trading, including WeShop Holdings Limited, which fell 38.8%, and Vizsla Silver Corp, which dropped 12.6% after announcing a convertible senior notes offering.

Market Reactions: Other notable declines included FinVolution Group down 5.6%, Kyverna Therapeutics down 5.1%, and NetEase Inc down 3.2%, reflecting a mixed market sentiment following various earnings reports.

FDA Feedback on uniQure's Gene Therapy: The FDA has expressed concerns regarding uniQure N.V.'s investigational gene therapy for Huntington's disease, AMT-130, indicating that the data from Phase 1/2 studies may not be sufficient for a Biologics License Application (BLA) submission.

Impact of FDA Leadership Changes: The absence of key FDA officials during the recent meeting, particularly Nicole Verdun, who was placed on administrative leave, has raised questions about the regulatory pathway for AMT-130 and contributed to a downgrade of uniQure's stock rating.

Regulatory Scrutiny on Gene Therapies: The FDA's comments suggest a tightening of regulations for gene and cell therapy programs, which could negatively affect other companies in the sector that have relied on similar trial designs.

Market Reaction: Following the FDA's feedback, uniQure's stock price fell by nearly 11%, reflecting investor concerns over the uncertainty surrounding the timing of the BLA submission and the overall regulatory environment for gene therapies.